New Research: Opioid Addiction and Dependence After Surgery

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known

Vast Majority of Surgeons Feel Pressure to Prescribe More Opioids than Patients Need

Professional Athlete Gabrielle Reece Joins Campaign to Promote Discussions Before Surgery about Non-Opioid Options for Pain Control

PARSIPPANY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- As the opioid epidemic rages on in the U.S., a new study finds that the use of opioids to treat pain after surgery is leading to addiction at alarming rates. According to a national survey, one in ten patients admit they’ve become addicted to or dependent on opioids after being exposed to these powerful medications following an operation. With 70 million surgical patients in the U.S. receiving an opioid annually, these findings suggest that as many as 7 million patients could develop an opioid addiction or dependency this year after surgery.

The rates of postsurgical opioid addiction and dependence are even higher for certain populations polled. Among younger people ages 18-29, the incidence is 15 percent*; for those living in the western region of the U.S., it soars to 18 percent.*

This research sheds new light on the causes of opioid addiction, which until now has primarily been focused on the use of opioids for treating patients with chronic pain. These findings indicate that even prescribing these drugs for short-term postsurgical pain can put patients at serious risk.

The survey polled 500 adults in the U.S. who had an orthopedic or soft tissue surgery in the past 12 months and 200 U.S. surgeons who perform these procedures. It was conducted by Wakefield Research on behalf of Pacira Pharmaceuticals, Inc. 

“Although potent pain relievers, opioids have long been associated with a range of unwanted and potentially severe side effects that can delay the patient recovery process including nausea, vomiting, constipation, and even respiratory depression. Now, these findings shine a significant spotlight on the role their use after surgery can play in contributing to our nation’s tragic opioid epidemic—a factor that, to date, has not been a major focus of attention,” said T.J. Gan, M.D., an anesthesiologist and President of the American Society of Enhanced Recovery (ASER). “Fortunately, there are several effective non-opioid options that are available for use before, during, and after surgery that help reduce patients’ need for opioids, thus limiting their risk for debilitating opioid-related side effects, or in the worst scenarios—addiction or dependence.”

Despite Risks, Pressure to Prescribe Opioids Remains High According to the national survey, almost all surgeons polled (94 percent) say they frequently prescribe opioids to manage postsurgical pain. Alarmingly, 91 percent indicated they frequently feel pressure to prescribe more opioids than their patients actually need.

As part of the Affordable Care Act, performance scores on publicly reported patient satisfaction surveys, including questions on how well a patient’s pain is controlled, are used to determine a portion of a hospital’s reimbursement from the Centers for Medicare & Medicaid Services (CMS). Numerous medical experts and organizations have called for CMS to remove those pain-related questions, arguing it unintentionally encourages the overprescribing of opioids to obtain high scores on the pain management section of the survey.

“There’s no doubt that doctors are often caught in the middle of policy and patient demands that can place undue burden on their prescribing habits,” continued Dr. Gan. “Now, more than ever, it’s critical to better educate hospitals, clinicians and, most importantly, patients about effective non-opioid options so all of us have the knowledge needed to choose alternatives to minimize or avoid opioids whenever appropriate in the hospital setting.” 

Choices Matter Launched to Foster Surgeon-Patient Dialogue The overwhelming majority of patients surveyed were highly aware of the risks associated with opioids; nearly 90 percent were concerned about side effects, addiction, or dependence and 79 percent would prefer a non-opioid pain management option. However, less than a quarter of patients say they discussed non-opioid options with their clinicians prior to surgery.

Given the clear need to cultivate better communication between patients and surgeons regarding all available postsurgical pain treatments, Pacira Pharmaceuticals and ASER are launching the Choices Matter program. The initiative aims to educate both patients and physicians about their options when it comes to postsurgical pain control in order to promote proactive discussions before surgery about non-opioid alternatives. Former star volleyball player, Gabrielle Reece, whose recent knee replacement surgery has made this issue personal, is joining the campaign.

“I knew pain would be a natural part of the recovery process following my knee replacement operation. Even before my surgery, I made a personal decision to not rely too heavily on opioids to manage my symptoms,” said Ms. Reece. “It’s great to know that non-opioid options exist and that strong prescription painkillers aren’t the only way to manage pain after surgery. Ultimately we’re the number one cheerleaders for our health so asking questions is key. The more information we have about our options, the better we can collaborate with our doctors on a personalized plan that gets us back on our feet again as quickly and safely as possible after surgery.”

For more information about postsurgical pain management options, including a customizable guide to facilitate a surgeon-patient discussion, visit www.PlanAgainstPain.com .   

About Pacira Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL ® (bupivacaine liposome injectable suspension), a non-opioid local analgesic for postsurgical pain control, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam ® , a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com .

About the American Society for Enhanced Recovery The American Society for Enhanced Recovery is a nonprofit organization with an international membership, and is dedicated to promoting the practice of optimizing patient preparation and recovery through education and research.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...26cb2f587e

 

Company Contact: Pacira Pharmaceuticals, Inc. Amber Sears, (973) 254-3587 Amber.Sears@pacira.com Media Contact: Coyne Public Relations Alyssa Schneider, 973-588-2270 aschneider@coynepr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BTQ Technologies Calls Investors for Key Quantum Update

Updated Category News Views 177

You know what's stirring the pot over at BTQ Technologies? A shareholder call coming up soon, and boy, it's got 'eye-opening insights' written all over it. We're talkin' Q3 financial results and, likely, a smattering of future plans on the quantum front, folks. Diving into BTQ's Quantum Vision BTQ Technologies Corp. (NASDAQ: BTQ) isn't just another tech firm banging on...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 194

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 137

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 133

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 193

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 197

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 138

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 255

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading

Top 5 Most Recently Viewed Articles

Inside FedEx: Recent Stock Options Exercise by Ramo Revealed

Updated Category News Views 121

Important Insider Activity at FedEx Recently, attention has turned to Joshua Cooper Ramo, a director of FedEx and his notable decision to exercise company stock options. This move, which was detailed in an SEC filing, reflects Ramo's strategic investment choices within the company. Details of the Stock Option Exercise While the specific exercise date details are...

Continue Reading
CTS's Upcoming Earnings Outlook and Market Insights

Updated Category News Views 140

Understanding CTS's Earnings Release Expectations CTS is set to release its quarterly earnings soon, and investors are keenly awaiting the announcement. Anticipation builds as analysts have forecasted an earnings per share (EPS) of $0.55 for the upcoming period. This news is important for stakeholders as it could influence stock prices significantly based on the results...

Continue Reading
Celebrating a New Beginning: Community Home Initiative in Greenville

Updated Category News Views 247

Revitalizing Greenville Through Community Efforts In a heartwarming event, local residents recently celebrated the completion of the first community-funded, single-family home in Greenville. The ceremony, which included a ribbon cutting and an open house, signifies hope and resilience for a community that has faced significant challenges. The Journey of Rebuilding The...

Continue Reading
Broad Arrow Auctions Sets New Records at 2025 Event

Updated Category News Views 343

Broad Arrow Auctions Sets New Records at 2025 Event In a spectacular display of collector car enthusiasm, Broad Arrow Auctions, a renowned Hagerty (NYSE: HGTY) company, shattered records during its prestigious Monterey Jet Center auction. Over two thrilling days, fervent bidders raised their paddles to secure stunning vehicles, culminating in an impressive total sale of...

Continue Reading
Investors Unite Against Everus Construction in Class Action

Updated Category News Views 177

Understanding the Class Action Lawsuit Against Everus Construction Group Investors are seizing an opportunity to take the lead in a class action lawsuit against Everus Construction Group, Inc. (NYSE: ECG). This lawsuit is specifically for those who purchased common stock of Everus Construction between certain dates. If you've acquired stock during this period, you might...

Continue Reading